Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy.
about
Discovery and development of natural product oridonin-inspired anticancer agentsActivities of N,N'-Diarylurea MMV665852 analogs against Schistosoma mansoniIdentification of STAT1 and STAT3 specific inhibitors using comparative virtual screening and docking validationSmall molecule inhibitors targeting activator protein 1 (AP-1).Recent advances in the discovery of small molecules targeting exchange proteins directly activated by cAMP (EPAC).Discovery of monocarbonyl curcumin-BTP hybrids as STAT3 inhibitors for drug-sensitive and drug-resistant breast cancer therapy.Therapeutic Potential of Spirooxindoles as Antiviral AgentsTherapeutic modulators of STAT signalling for human diseasesTranscription Factor STAT3 as a Novel Molecular Target for Cancer Prevention.Discovery of potent anticancer agent HJC0416, an orally bioavailable small molecule inhibitor of signal transducer and activator of transcription 3 (STAT3).Evolutions in fragment-based drug design: the deconstruction-reconstruction approachFragment-based strategy for structural optimization in combination with 3D-QSAR.STAT3 modulation to enhance motor neuron differentiation in human neural stem cells.BH4 domain of Bcl-2 as a novel target for cancer therapyEPHA3 regulates the multidrug resistance of small cell lung cancer via the PI3K/BMX/STAT3 signaling pathway.Cancer drug delivery in the nano era: An overview and perspectives (Review)Exchange proteins directly activated by cAMP (EPACs): Emerging therapeutic targets.Synthesis, Characterization and Anti-Cancer Activity of Hydrazide Derivatives Incorporating a Quinoline Moiety.Novel carbazole inhibits phospho-STAT3 through induction of protein-tyrosine phosphatase PTPN6.STAT3 Inhibition Suppresses Hepatic Stellate Cell Fibrogenesis: HJC0123, a Potential Therapeutic Agent for Liver Fibrosis.Molecular design of Stat3-derived peptide selectivity between BET proteins Brd2 and Brd4 in ovarian cancer.Targeting the IL-6/JAK/STAT3 signalling axis in cancer.A new synthetic derivative of cryptotanshinone KYZ3 as STAT3 inhibitor for triple-negative breast cancer therapyA high-throughput fluorescence polarization assay for discovering inhibitors targeting the DNA-binding domain of signal transducer and activator of transcription 3 (STAT3)
P2860
Q28387804-BD94738A-4FCD-4C0D-889D-6AA5AC4DC954Q28389729-BE995C60-829B-4E9A-AF64-7FFBD2227AB1Q28543632-7A066CA8-27F9-4C38-B48F-6171FCD61E3EQ30398272-1101EC2C-D320-41AA-9FCE-3467A9464966Q30405298-C980A961-F599-4A92-82A3-76F5BA756889Q33551693-25646492-48DA-426A-8707-D6332A99B97DQ33637160-47656F69-76AD-48EF-A51F-6036A2EFA413Q33684732-F63151C4-C330-47A2-B56B-FAEE611C0F16Q33820278-ECDC1EE8-A58D-4D21-A9F2-77C59470B84BQ33897006-19DBF586-2562-4635-92A6-AC160045FEB0Q35009555-625E743B-F7FB-4C03-90FE-4A9B38D44DF5Q35030073-17DD0E91-73C3-4B1A-BC80-F725ED9AD748Q35191149-B71DD7E6-1A77-459C-B6FD-87BBBA7FFBF0Q36940766-80950EC1-1CB7-452C-AD59-752B7F8D3409Q37366277-9263186D-2F67-4E7C-B930-149928253F72Q38669454-78ECF9D4-FF43-4EC1-BAEE-0A263F0A0F2FQ38747476-2E349B1F-3878-4AD5-A0F9-CFC4A20B54CFQ38757478-C12B485C-2772-44E2-A6C8-EEC3ACAD1196Q38979718-69C42474-656E-43AE-B481-A298F5B2E8E6Q42234685-DE480942-179D-4BFC-9473-B6ACAA34800EQ47688490-5DF7852B-98C0-491B-85E5-93F648E8E59FQ50191433-D53CC435-32E6-451B-94B8-EFEBB078DF80Q58110122-799F06AD-0E1D-4FEC-848A-7AC16D027847Q58704632-D40F6235-8D6B-4F65-AAEC-C6AE47832DC8
P2860
Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 January 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Fragment-based drug design and ...... inhibitor for cancer therapy.
@en
Fragment-based drug design and ...... inhibitor for cancer therapy.
@nl
type
label
Fragment-based drug design and ...... inhibitor for cancer therapy.
@en
Fragment-based drug design and ...... inhibitor for cancer therapy.
@nl
prefLabel
Fragment-based drug design and ...... inhibitor for cancer therapy.
@en
Fragment-based drug design and ...... inhibitor for cancer therapy.
@nl
P2093
P2860
P1476
Fragment-based drug design and ...... 3 inhibitor for cancer therapy
@en
P2093
Chunyong Ding
Haijun Chen
Huiling Liu
Kristin Terry
Yusong Zhang
Zhengduo Yang
P2860
P304
P356
10.1016/J.EJMECH.2013.01.023
P50
P577
2013-01-26T00:00:00Z